pellicle
Professional Dingbat, Guru and Merkintologist
I read this interesting article this morning
https://www.dw.com/en/astrazeneca-german-team-discovers-thrombosis-trigger/a-56925550
which led me to google a bit and uncover this:
https://www.eurekalert.org/pub_releases/2021-04/aha-got042921.php
which makes clear that NON-Heparin anticoagulants be administered in the case of a clot. This suggests that as I've said here before: those of us on anticoagulants are already protected. The Anticoagulant family suggested has in common:
https://en.wikipedia.org/wiki/Bivalirudin
although
https://en.wikipedia.org/wiki/Danaparoid
is indirect, suggesting that warfarin will still be of use.
I didn't put this in "New Developments" because while it is, its not a heart valve new development, nor really an Anticoagulation topic.
https://www.dw.com/en/astrazeneca-german-team-discovers-thrombosis-trigger/a-56925550
which led me to google a bit and uncover this:
https://www.eurekalert.org/pub_releases/2021-04/aha-got042921.php
- All patients with suspected CVST due to a COVID-19 vaccine should be treated with non-heparin anticoagulants such as argatroban, bivalirudin, danaparoid, fondaparinux or a direct oral anti-coagulant (DOAC). No heparin products in any dose should be given.
which makes clear that NON-Heparin anticoagulants be administered in the case of a clot. This suggests that as I've said here before: those of us on anticoagulants are already protected. The Anticoagulant family suggested has in common:
- direct thrombin inhibitor
- rapid onset
- short half life
https://en.wikipedia.org/wiki/Bivalirudin
although
https://en.wikipedia.org/wiki/Danaparoid
is indirect, suggesting that warfarin will still be of use.
I didn't put this in "New Developments" because while it is, its not a heart valve new development, nor really an Anticoagulation topic.